Development of lecithinized superoxide dismutase as a drug for IPF

Tohru Mizushima

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) are thought to involve lung injury induced by reactive oxygen species (ROS), in particular superoxide anion. The enzyme, superoxide dismutase (SOD) catalyses the dismutation of superoxide anion to hydrogen peroxide. Lecithinized SOD (PC-SOD) has overcome a number of previous clinical limitations of SOD, including low tissue affinity and low stability in plasma. Recent animal studies suggest that PC-SOD is effective for the treatment of IPF and COPD. We are now performing the clinical study of PC-SOD for IPF patients.

Original languageEnglish
Pages (from-to)69-76
Number of pages8
JournalYakugaku Zasshi
Issue number1
Publication statusPublished - 2014
Externally publishedYes


  • Idiopathic pulmonary fibrosis
  • Reactive oxygen species
  • Superoxide dismutase

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science


Dive into the research topics of 'Development of lecithinized superoxide dismutase as a drug for IPF'. Together they form a unique fingerprint.

Cite this